乳癌是一種異質性極高的疾病，即便臨床期別相同，未來復發機會也可能有很大的差異。乳癌的復發可分為區域復發（local regional recurrence, LRR）與遠端轉移（distant metastasis）。透過術後放射線治療可減少區域復發，術後接受化學藥物治療則可減少遠端轉移。

瑞可盈^®乳癌復發風險檢測技術的核心價值，在於能精準解碼病人基因，判斷區域復發與遠處轉移的風險，給予病人最佳化的個人化醫療。

若病人為低風險族群，則可避免過度化學藥物治療與放射線治療；若病人為高風險族群，則可供醫師增加化學藥物治療及區域放射線治療之輔助參考。

透過這樣的進階分析，能讓病人在早期發現罹癌時接受必要治療，減少家庭及社會的長期負擔，達到個人化精準醫療、降低死亡率。

1. A 23-gene prognostic classifier for prediction of recurrence and survival for Asian breast cancer patient
   Ting-Hao Chen, Jian-Ying Chiu and Kuan-Hui Shih. 2020, Volume 40, Bioscience Reports.

2. A Clinicogenetic Prognostic Classifier for Prediction of Recurrence and Survival in Asian Breast Cancer Patients
   Ting-Hao Chen, Jun-Ru Wei, Jason Lei, Jian-Ying Chiu and Kuan-Hui Shih. 2021, Volume 11, Frontiers in Oncology.

3. Cost-Effectiveness Analysis from a Societal Perspective of Recurrence Index for Distant Recurrence (RecurIndex) in Women with Hormone Receptor-Positive and HER2-Negative Early-Stage Breast Cancer
   Nicolas Pennarhiu, Hsun-Chen Chang, Sean-Lin Huang, Skye Hung-Chun Chengun, Jian-Ying C. 2022, 14: 761, Cancer Management and Research.

4. Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
   Chih-Jung Chen, Ting-Hao Chen, Jason Lei, Ji-An Liang, Po-Sheng Yang, Chiun-Sheng Huang, Chia-Ming Hsieh, Ling-Ming Tseng, Liang-Chih Liu, Skye Hung-Chen Cheng and Kuan-Hui Shih. 2022, 42.1: BSR20211706, Bioscience Reports.